Urokinase-type plasminogen activator deficiency has little effect on seizure susceptibility and acquired epilepsy phenotype but reduces spontaneous exploration in mice

Epilepsy and Behavior

Volumn 42, Issue , 2015, Pages 117-128

  Rantala, J ^a   Kemppainen, S ^a   Ndode Ekane, X E ^a   Lahtinen, L ^a   Bolkvadze, Tamuna ^a   Gurevicius, K ^a   Tanila, H ^a,b   Pitkanen A ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Anxiety; Epileptogenesis; Memory; Neurophenotyping; Social anxiety; UPAR interactome

Indexed keywords

KAINIC ACID; PENTETRAZOLE; PILOCARPINE; UROKINASE; UROKINASE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; BEHAVIOR; BRAIN INJURY; CONTROLLED STUDY; EPILEPSY; EPILEPTOGENESIS; EVOKED AUDITORY RESPONSE; EXPLORATORY BEHAVIOR; FEAR; HIPPOCAMPUS; HYPOTHESIS; MALE; MEMORY; MOTOR COORDINATION; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; PAIN THRESHOLD; PHENOTYPE; SEIZURE SUSCEPTIBILITY; SENSORY DYSFUNCTION; SPATIAL MEMORY; WILD TYPE; ANIMAL; ANIMAL BEHAVIOR; C57BL MOUSE; DEFICIENCY; DISEASE PREDISPOSITION; ELECTROENCEPHALOGRAPHY; GENETICS; KNOCKOUT MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; SEIZURE;

ANIMALS; BEHAVIOR, ANIMAL; DISEASE SUSCEPTIBILITY; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS, AUDITORY; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHENOTYPE; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SEIZURES; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84916896936     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2014.11.001     Document Type: Article

References (52)

1. Lukasiuk K., Kontula L., Pitkänen A. cDNA profiling of epileptogenesis in the rat brain. Eur J Neurosci 2003, 17:271-279.
2. Gorter J.A., van Vliet E.A., Aronica E., Breit T., Rauwerda H., Lopes da Silva F.H., et al. Potential new antiepileptogenic targets indicated by microarray analysis in a rat model for temporal lobe epilepsy. J Neurosci 2006, 26:11083-11110.
3. Cunningham O., Campion S., Perry V.H., Murray C., Sidenius N., Docagne F., et al. Microglia and the urokinase plasminogen activator receptor/uPA system in innate brain inflammation. Glia 2009, 57:1802-1814.
4. Iyer A.M., Zurolo E., Boer K., Baayen J.C., Giangaspero F., Arcella A., et al. Tissue plasminogen activator and urokinase plasminogen activator in human epileptogenic pathologies. Neuroscience 2010, 167:929-945.
5. Alfano D., Franco P., Vocca I., Gambi N., Pisa V., Mancini A., et al. The urokinase plasminogen activator and its receptor: role in cell growth and apoptosis. Thromb Haemost 2005, 93:205-211.
6. Blasi F., Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002, 3:932-943.
7. Pitkänen A., Lukasiuk K. Molecular and cellular basis of epileptogenesis in symptomatic epilepsy. Epilepsy Behav 2009, 14(Suppl. 1):16-25.
8. Blasi F., Sidenius N. The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett 2010, 584:1923-1930.
9. Smith H.W., Marshall C.J. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 2010, 11:23-36.
10. Powell E.M., Campbell D.B., Stanwood G.D., Davis C., Noebels J.L., Levitt P. Genetic disruption of cortical interneuron development causes region- and GABA cell type-specific deficits, epilepsy, and behavioral dysfunction. J Neurosci 2003, 23:622-631.
11. Levitt P., Eagleson K.L., Powell E.M. Regulation of neocortical interneuron development and the implications for neurodevelopmental disorders. Trends Neurosci 2004, 27:400-406.
12. Eagleson K.L., Bonnin A., Levitt P. Region- and age-specific deficits in gamma-aminobutyric acidergic neuron development in the telencephalon of the uPAR(-/-) mouse. J Comp Neurol 2005, 489:449-466.
13. Lahtinen L., Lukasiuk K., Pitkänen A. Increased expression and activity of urokinase-type plasminogen activator during epileptogenesis. Eur J Neurosci 2006, 24:1935-1945.
14. Lahtinen L., Huusko N., Myöhänen H., Lehtivarjo A.-K., Pellinen R., Turunen M.P., et al. Expression of urokinase-type plasminogen activator receptor is increased during epileptogenesis in the rat hippocampus. Neuroscience 2009, 163:316-328.
15. Wu F., Catano M., Echeverry R., Torre E., Haile W.B., An J., Chen C., Cheng L., Nicholson A., Tong F.C., Park J., Yepes M. Urokinase-type plasminogen activator promotes dendritic spine recovery and improves neurological outcome following ischemic stroke. J Neurosci 2014, 34(43):14219-14232.
16. Bruneau N., Szepetowski P. The role of the urokinase receptor in epilepsy, in disorders of language, cognition, communication and behavior, and in the central nervous system. Curr Pharm Des 2011, 17:1914-1923.
17. Campell D.B., Li C., Sutcliffe J.S., Persico A.M., Levitt P. Genetic evidence implicating multiple genes in the MET receptor tyrosine kinase pathway in autism spectrum disorder. Autism Res 2008, 1:159-168.
18. Eagleson K.L., Gravielle M.C., Schlueter McFadyen-Ketchum L.J., Russek S.J., Farb D.H., Levitt P. Genetic disruption of the autism spectrum disorder risk gene PLAUR induces GABAA receptor subunit changes. Neuroscience 2010, 168:797-810.
19. Bissonette G.B., Bae M.H., Suresh T., Jaffe D.E., Powell E.M. Prefrontal cognitive deficits in mice with altered cerebral cortical GABAergic interneurons. Behav Brain Res 2014, 259:143-151.
20. Roll P., Rudolf G., Pereira S., Royer B., Scheffer I.E., Massacrier A., et al. SRPX2 mutations in disorders of language cortex and cognition. Hum Mol Genet 2006, 15:1195-1207.
21. Reinthaler E.M., Lal D., Jurkowski W., Feucht M., Steinböck H., Gruber-Sedlmayr U., et al. Analysis of ELP4, SRPX2, and interacting genes in typical and atypical rolandic epilepsy. Epilepsia 2014, 55:e89-e93.
22. Morales D., McIntosh T., Conte V., Fujimoto S., Graham D., Grady M.S., et al. Impaired fibrinolysis and traumatic brain injury in mice. J Neurotrauma 2006, 23:976-984.
23. Lahtinen L., Ndode-Ekane X.E., Barinka F., Akamine Y., Esmaeili M.H., Rantala J., et al. Urokinase-type plasminogen activator regulates neurodegeneration and neurogenesis but not vascular changes in the mouse hippocampus after status epilepticus. Neurobiol Dis 2010, 37:692-703.
24. Carmeliet P., Schoonjans L., Kieckens L., Ream B., Degen J., Bronson R., et al. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994, 368:419-424.
25. Yiou R., Delmas V., Carmeliet P., Gherardi R.K., Barlovatz-Meimon G., Chopin D.K., et al. The pathophysiology of pelvic floor disorders: evidence from a histomorphologic study of the perineum and a mouse model of rectal prolapse. J Anat 2001, 199:599-607.
26. Jensen P.J., Lavker R.M. Urokinase is a positive regulator of epidermal proliferation in vivo. J Investig Dermatol 1999, 112:240-244.
27. Daci E., Everts V., Torrekens S., Van Herck E., Tigchelaar-Gutterr W., Bouillon R., et al. Increased bone formation in mice lacking plasminogen activators. J Bone Miner Res 2003, 18:1167-1176.
28. Shapiro R.L., Duquette J.G., Nunes I., Roses D.F., Harris M.N., Wilson E.L., et al. Urokinase-type plasminogen activator-deficient mice are predisposed to staphylococcal botryomycosis, pleuritis, and effacement of lymphoid follicles. Am J Pathol 1997, 150:359-369.
29. Lijnen H.R., Van Hoef B., Lupu F., Moons L., Carmeliet P., Collen D. Function of the Plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes. Arterioscler Thromb Vasc Biol 1998, 18:1035-1045.
30. Lluís F., Roma J., Suelves M., Parra M., Aniorte G., Gallardo E., et al. Urokinase-dependent plasminogen activation is required for efficient skeletal muscle regeneration in vivo. Blood 2001, 97:1703-1711.
31. Drixler T.A., Vogten J.M., Gebbink M.F.B.G., Carmeliet P., Voest E.E., Borel Rinkes I.H.M. Plasminogen mediates liver regeneration and angiogenesis after experimental partial hepatectomy. Br J Surg 2003, 90:1384-1390.
32. Suelves M., Vidal B., Serrano A.L., Tjwa M., Roma J., López-Alemany R., et al. uPA deficiency exacerbates muscular dystrophy in MDX mice. J Cell Biol 2007, 178:1039-1051.
33. Gyetko M.R., Chen G.H., McDonald R.A., Goodman R., Huffnagle G.B., Wilkinson C.C., et al. Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans. A murine transgenic model. J Clin Invest 1996, 97:1818-1826.
34. Gyetko M.R., Sud S., Chensue S.W. Urokinase-deficient mice fail to generate a type 2 immune response following schistosomal antigen challenge. Infect Immun 2004, 72:461-467.
35. Frandsen T.L., Holst-Hansen C., Nielsen B.S., Christensen I.J., Nyengaard J.R., Carmeliet P., et al. Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model. Cancer Res 2001, 61:532-537.
36. Almholt K., Lund L.R., Rygaard J., Nielsen B.S., Danø K., Rømer J., et al. Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice. Int J Cancer 2005, 113(4):525-532.
37. Hof P.R., Young W.G., Bloom F.E., Belichenko P.V., Celio M.R. Comparative cytoarchitectonic atlas of the C57BL/6 and 129/SV mouse brains 2000, Elsevier Scince B.V., Amsterdam.
38. Nissinen J., Halonen T., Koivisto E., Pitkänen A. A new model of chronic temporal lobe epilepsy induced by electrical stimulation of the amygdala in rat. Epilepsy Res 2000, 38:177-205.
39. Racine R.J. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr Clin Neurophysiol 1972, 32:281-294.
40. Halonen T., Nissinen J., Pitkänen A. Effect of lamotrigine treatment on status epilepticus-induced neuronal damage and memory impairment in rat. Epilepsy Res 2001, 46:205-223.
41. http://biosig.sourceforge.net/.
42. Bickford-Wimer P.C., Nagamoto H., Johnson R., Adler L.E., Egan M., Rose G.M., et al. Auditory sensory gating in hippocampal neurons: a model system in the rat. Biol Psychiatry 1990, 27:183-192.
43. Kharatishvili I., Nissinen J.P., McIntosh T.K., Pitkänen A. A model of posttraumatic epilepsy induced by lateral fluid-percussion brain injury in rats. Neuroscience 2006, 140:685-697.
44. Pitkänen A., Kharatishvili I., Narkilahti S., Lukasiuk K., Nissinen J. Administration of diazepam during status epilepticus reduces development and severity of epilepsy in rat. Epilepsy Res 2005, 63:27-42.
45. Phillips R.G., LeDoux J.E. Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. Behav Neurosci 1992, 106:274-285.
46. Pitkänen A., Ndode-Ekane X.E., Lukasiuk K., Wilczynski G.M., Dityatev A., Walker M.C., Chabrol E., Dedeurwaerdere S., Vazquez N., Powell E.M. Neural ECM and epilepsy. Prog Brain Res 2014, 214:229-262.
47. Morris R.G., Garrud P., Rawlins J.N., O'Keefe J. Place navigation impaired in rats with hippocampal lesions. Nature 1982, 297:681-683.
48. Anagnostaras S.G., Gale G.D., Fanselow M.S. Hippocampus and contextual fear conditioning: recent controversies and advances. Hippocampus 2001, 11:8-17.
49. Ji J., Maren S. Hippocampal involvement in contextual modulation of fear extinction. Hippocampus 2007, 17:749-758.
50. LeDoux J.E. Emotional memory systems in the brain. Behav Brain Res 1993, 58:69-79.
51. Delgado M.R., Nearing K.I., Ledoux J.E., Phelps E.A. Neural circuitry underlying the regulation of conditioned fear and its relation to extinction. Neuron 2008, 59:829-838.
52. Royer-Zemmour B., Ponsole-Lenfant M., Gara H., Roll P., Lévêque C., Massacrier A., et al. Epileptic and developmental disorders of the speech cortex: ligand/receptor interaction of wild-type and mutant SRPX2 with the plasminogen activator receptor uPAR. Hum Mol Genet 2008, 17:3617-3630.